Find a local office
- This event has passed.
2nd Lung Cancer Screening & Continuum Of Care
Routine CT lung cancer screening of high-risk individuals would save thousands of lives per year for less than a dollar a month per patient if it were implemented throughout the U.S. and would be even cheaper than breast screening.
Small dosage CT screening for lung cancer carried out safely, proficiently and rightfully has become a popular procedure for those diagnosed with Lung Cancer. Drawing knowledge from other screening histories, and from the recent support of the effectiveness of CT screening in a high risk population, it is clear that achieving this goal will require a well-informed public and the commitment of medical professionals to institute best practices. Advances in imaging and biomedical research will continue to evolve rapidly. The breach of CT screening into the healthcare system presents a unique opportunity to develop a coexisting mechanism for collecting data and specimens to accelerate that research and for introducing refinements into the screening process as imaging and biomedical advances occur and is validated.
Given the increasing number of hospitals who study lung cancer, this conference has been developed to provide a forum to all physicians and educators. This multidisciplinary meeting will promote interaction between Medical Oncologists, Radiation Oncologists and Principle Investigators to achieve the best possible outcome for thoracic cancer patients.
Featuring a Tour of the H. Lee Moffitt Cancer Center and Research Institute
Located in Tampa FL, Moffitt is one of only 41 National Cancer Institute-designated Comprehensive Cancer Centers, a distinction that recognizes Moffitt’s excellence in research, its contributions to clinical trials, prevention and cancer control. Since 1999, Moffitt has been listed in U.S. News & World Report as one of “America’s Best Hospitals” for cancer. With more than 4,200 employees, Moffitt has an economic impact on the state of nearly $2 billion.
Past Lung Cancer Screening Conference
- Identifying Patients at high risk for the development of lung cancer.
- Understanding some of the challenges for implementation of a Low Dose CT screening program, and receive tools to address such challenges.
- Review the guidelines regarding patient selection for Low Dose CT screening.
- Lung Cancer Screening and Smoking Cessation.
- Developing clinical protocols for promoting smoking cessation in Lung Cancer Screening settings.
- Essential elements needed to initiate and maintain a screening program.
- Implementing strategies to appropriately screen and ensure patient follow up.
- Developing a comprehensive Lung Cancer Screening program as a center of excellence.
- How to deploy lung cancer screening responsibly and equitably.
- How to approach on building a Lung Cancer Screening program from the ground up; benefits behind service line development.
- Exploring the latest advances in CT imaging and biomedical research.
- Best practices for controlling screening quality, radiation dose, and diagnostic procedures.
- Administrative aspects of operating a Lung Cancer Screening program, and multi-disciplinary view points from the non-physician perspective.
- Analysis and reporting mechanisms for results in existing Lung Cancer Screening Programs and Centers.
- Discussing how much would a screening program would cost, if implemented on a national scale.
Senior-level executives representing Hospitals, Health Systems, Physician Clinics & Hospital Management Groups:
- Medical Oncologists
- Radiation Oncologists
- Principle Investigators
- Pulmonologists
- Internal Medicine Physicians
- Family Practice Physicians
- Physical Therapists
- Respiratory Therapists
- Physician Assistants
- CT Scanning Companies
- Nurse Navigators
- Oncology Nurse Navigators
ONC Immune
Oncimmune® is a privately funded company located in Nottingham, UK with US headquarters and a CLIA-certified laboratory in Kansas City. In 2006, the company launched a proprietary platform technology for early cancer detection, called EarlyCDT®, which measures autoantibodies (immuno-biomarkers) in blood that form early in carcinogenesis. Numerous publications report that autoantibodies may be present up to 5 years before a tumor is visible by imaging, as depicted in Figure 1. These autoantibodies are produced in response to the presence of certain by-products from cancer cells (i.e., proteins called antigens). When the body recognizes something as “non-self”, one of the ways it responds is for the immune system to produce large amounts of antibodies. The immune system does not normally produce antibodies against normal tissue antigens; therefore, these immuno-biomarkers to cancer antigens provide high specificity for cancer. Tests that detect autoantibodies to a single tumor protein have been available for a number of years but have had low detection capabilities (sensitivity). Previously, multiple antigen tests had low specificity, especially for early detection.
Website: www.earlycdt-lung.co.uk
Quest Diagnostics
At Quest Diagnostics our vision is: Empowering Better Health with Diagnostic Insights. We provide crucial diagnostic information that supports and enhances decisions people make to improve patients’ health. We know the choices that healthcare professionals, patients, and health plans make will shape the future of human health and we are committed to making sure those choices are well-informed. We invite you to view our Empowering Better Health video, which shows the impact we have on so many people’s lives. We look forward to helping you unlock the insights and power of diagnostic testing.
Website: www.questdiagnostics.com
Siemens Healthcare
The Siemens Healthcare Sector is one of the world’s largest suppliers to the healthcare industry and a trendsetter in medical imaging, laboratory diagnostics, medical information technology and hearing aids. Siemens offers its customers products and solutions for the entire range of patient care from a single source – from prevention and early detection to diagnosis, and on to treatment and aftercare. By optimizing clinical workflows for the most common diseases, Siemens also makes healthcare faster, better and more cost-effective. Siemens Healthcare employs some 51,000 employees worldwide and operates around the world. In fiscal year 2011 (to September 30), the Sector posted revenue of 12.5 billion euros and profit of around 1.3 billion euros.
Website: www.siemens.com
SPi Healthcare
SPi Healthcare is the industry’s leading integrated revenue cycle and clinical documentation improvement firm. For more than 26 years we have been delivering the experience and expertise you need to fine-tune your operations and realize your organization’s peak performance, just as we have for countless providers throughout North America. Our full-spectrum approach is unique in the industry, designed to help you accelerate cash flow and mitigate the unnecessary and costly risks associated with inferior physician billing and collections, coding and clinical documentation.
Website: www.spihealthcare.com
superDimension / Covidien
superDimension is a privately-held medical device company that develops and markets minimally-invasive pulmonology devices that enable the diagnosis and potentially the treatment of distal lung disease. Our product line, the i·LogicTM System, includes both capital equipment and disposables, addressing a total available market of more than 8 million patients.
Driven by our mission, “To be the world leader in the diagnosis and treatment of distal lung disease,” we are focused on extending the capabilities of traditional bronchoscopy tools to help diagnose previously inaccessible lung lesions at an earlier stage when they may be easier to treat.
Website: www.superdimension.com
Lung Cancer Alliance
Lung Cancer Alliance is the only national non-profit organization dedicated solely to providing support and advocacy for people living with or at risk for the disease. Our mission ending injustice and saving lives through an alliance of advocacy, education and support. Our vision is to reduce lung cancer mortality by at least 50% by 2020. Founded in 1995, our first priority and founding hallmark is to meet the needs of lung cancer patients and those at risk. As the largest lung cancer advocacy organization in the world, we work tirelessly to improve outcomes, eliminate stigma and secure public health research dollars. Thanks primarily to the support of thousands of individuals who initially get help from us and then in turn desire to give back, we have met many milestones.
Website: www.lungcanceralliance.org
Caring Ambassadors Program, Inc.
The Caring Ambassadors Lung Cancer Program is a national nonprofit organization devoted to increasing the wellness and longevity of people affected by lung cancer through information, awareness, and interpersonal support. The Caring Ambassadors Program is proud to announce the release of two new resources for people with lung cancer and their loved ones. The 2nd Edition of Lung Cancer Choices and a new publication, Caregiver Choices. Lung Cancer Choices can be a useful tool for anyone who is caring for someone with lung cancer, but its primary focus is on the patient. Caregiver Choices focuses on the unique challenges of caring for someone with lung cancer and provides caregivers with tools and resources for the road ahead. Both publications are available online for free in PDF format.
Website: www.lungcancercap.org